New Study Aims to End Guesswork in ICU Pneumonia Diagnosis
Researchers across five European countries are launching a major study to identify distinct subtypes of ventilator-associated pneumonia using protein analysis, a move that could slash unnecessary antibiotics in hospitals and cut treatment costs. Current diagnostic methods are too imprecise, leading doctors to prescribe antibiotics broadly when a patient's breathing worsens—even when infection isn't the cause.
Originaltitel: ClusterVAP: study protocol for multicentre proteomic endotyping of ventilator-associated pneumonia
<p>INTRODUCTION: Ventilator-associated pneumonia (VAP) is the most frequent healthcare-associated infection in intensive care units and is associated with high morbidity and mortality. Current diagnostic criteria lack specificity, leading to misclassification and unnecessary antibiotic use. Identifying patient subgroups with a common pathophysiological basis (pneumoclusters) may distinguish true VAP of varying aetiology and severity from non-infectious mimics, enabling more targeted therapy and improved antimicrobial stewardship.</p><p>METHODS AND ANALYSIS: ClusterVAP is an exploratory, observational, prospective, multicentre cross-sectional study conducted in intensive care units across Sweden, France, Portugal, Denmark and the UK. Mechanically ventilated patients aged 18 years or older with newly developed clinical signs of lower respiratory tract infection will undergo bronchoalveolar lavage (BAL) or mini BAL sampling on clinical indication. Proteomic profiling using liquid chromatography tandem mass spectrometry will be performed on BAL supernatants. Unsupervised consensus clustering will define pneumoclusters, which will be characterised using clinical, microbiological and radiological data. 30-day outcomes, including mortality, ventilator-free days, antibiotic-free days, intensive care unit-free days and hospital-free days, will be compared across clusters to describe clinical trajectories. Candidate protein biomarkers for pragmatic cluster assignment will be derived using differential expression analysis.</p><p>ETHICS AND DISSEMINATION: Ethical approval will be obtained at all participating sites. Deferred consent will be used where permitted, with subsequent patient or proxy consent according to local regulations. Results will be disseminated through peer-reviewed publications and scientific conferences.</p><p>TRIAL REGISTRATION NUMBER: NCT07245888.</p>